DOI: 10.1128/AAC.00959-17
Article Information
PubMed
Published By
History
- Received May 8, 2017
- Returned for modification June 9, 2017
- Accepted August 8, 2017
- Published online October 24, 2017.
Copyright & Usage
Copyright © 2017 Hoover et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license
.
Article Versions
- Accepted Manuscript version (August 14, 2017).
- You are viewing the most recent version of this article.
Author Information
- Jennifer L. Hoover,
- Christine M. Singley,
- Philippa Elefante,
- Peter DeMarsh,
- Magdalena Zalacain and
- Stephen Rittenhouse
- Address correspondence to Jennifer L. Hoover, jennifer.l.hoover{at}gsk.com.
Citation Hoover JL, Singley CM, Elefante P, DeMarsh P, Zalacain M, Rittenhouse S. 2017. Reducing antibacterial development risk for GSK1322322 by exploring potential human dose regimens in nonclinical efficacy studies using immunocompetent rats. Antimicrob Agents Chemother 61:e00959-17. https://doi.org/10.1128/AAC.00959-17 .
